Evercore ISI maintains CVS Health stock rating amid spinoff reports

CVS Health is reportedly considering spinning off its approximately 9,000-store retail pharmacy business, potentially by the first half of 2028, while keeping Caremark with the remaining business; the structure and timing could change. Evercore ISI reiterated Outperform and a $125 price target, but called the deal complex with significant execution risk; TD Cowen estimated about $71 billion in proceeds using a sum-of-the-parts valuation. CVS is scheduled to report third-quarter 2026 results Wednesday, and options data indicate a possible 5.8% stock move.

Analysis

The key potential value driver is not a mechanical breakup premium; it is whether separating the store network changes the economics or merely relocates costs and regulatory scrutiny. A standalone retailer could have weaker bargaining leverage with drugmakers and payers, while CVS retaining Caremark preserves an integrated PBM-pharmacy relationship elsewhere in the group. That may reduce one state-level conflict, but it does not remove scrutiny of PBM practices or guarantee regulatory relief. Separation could also leave the retail company with less attractive scale and stranded corporate costs, while CVS’s remaining business inherits transition and allocation disputes.

Treat the reported $71bn figure as a sum-of-the-parts valuation indication, not cash proceeds: a conventional spin distributes shares and does not itself raise equivalent cash for CVS. The missing inputs are segment-level standalone earnings/cash flow, debt and overhead allocation, separation costs, and the actual transaction structure. Without them, a breakup multiple is not yet investable.

Near term, earnings and any formal transaction detail may dominate the stock; the reported options-implied move argues against treating the event as a low-volatility catalyst. Over 1–3 months, watch for board approval, segment disclosures, and a credible separation timetable. Over 6–18 months, execution, retail cash generation, and PBM regulation matter more than headline valuation. The thesis weakens if management offers no decision-grade segment data, postpones the plan, or retail economics deteriorate enough to overwhelm any sum-of-parts benefit.

Key Decisions for Investors

• Avoid adding directional exposure solely on breakup headlines ahead of earnings. If already long CVS, size for the event risk and reassess after guidance and any quantified separation disclosures; do not interpret analyst targets or a SOTP estimate as transaction value.
• Set an alert for segment-level operating profit/cash flow, debt and stranded-cost allocations, separation expense, and whether the structure is a true spin or another form of separation. No transaction-specific recommendation until these are disclosed.
• Consider a staged long only if CVS provides credible standalone economics and the market does not price in unsupported cash proceeds; use post-earnings entry rather than chasing a pre-event gap. Falsify on a delayed/abandoned plan or materially weaker retail cash generation.
• Track PBM-related state or federal actions as a downside catalyst: a retail separation may ease one vertical-ownership concern but does not insulate Caremark from broader PBM regulation.